• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Collegium Internationale Allergologicum >Anti-IgE Treatment Overcomes Intolerability of Honeybee- Venom Ultra-Rush Immunotherapy in Indolent Systemic Mastocytosis
【24h】

Anti-IgE Treatment Overcomes Intolerability of Honeybee- Venom Ultra-Rush Immunotherapy in Indolent Systemic Mastocytosis

机译：抗IgE治疗克服了蜜腺超鼠疫免疫疗法在惰性全身乳细胞诱变中的不耐受性

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with elevated serum tryptase/mastocytosis are at risk for severe and fatal reactions following hymenoptera stings and can be unable to undergo venom immunotherapy because of intolerable side effects. We report the first case of a patient with indolent systemic mastocytosis and recurrent severe anaphylaxis to field stings and to venom immunotherapy, in whom a single dose of 150 mg omalizumab enabled ultra-rush honey bee venom immunotherapy. Immunotherapy (IT) with hymenoptera venom reduces the risk of anaphylaxis with subsequent stings and is recommended in patients with systemic reactions and evidence of venom-specific IgE. Treatment with honey bee venom (HBV) induces anaphylactic reactions more frequently than yellow jacket venom [1]. Patients with elevated basal serum tryptase levels/mastocytosis are at risk for more-severe and even fatal reactions following stings and may be unable to undergo venom IT [2, 3].We report the first case of a patient with indolent systemic mastocytosis and recurrent severe anaphylaxis to field stings and venom IT, in whom a single dose of omalizumab enabled ultra-rush IT within two days [4] with a total dose of 351.11 mg HBV (ALK SQ, Abello, Horsholm, DK). Thereafter, ten maintenance doses of HBV (100 mg) were tolerated.
机译：血清胰蛋白酶/乳腺诱导率升高的患者处于Hymenoptera围栏后严重和致命反应的风险，并且由于易于涉及的副作用，可能无法接受毒液免疫疗法。我们报告了患有惰性全身乳细胞增长症的第一种患者和经常性的严重过敏性，对毒液围栏和毒液免疫疗法，其中一剂150mg omalizumab使能紫外蜂蜜蜜蜂免疫疗法。 Hymenoptera毒液的免疫疗法（IT）降低了随后的围栏的过敏反应的风险，并建议在具有血清特异性IgE的系统性反应和证据患者中。用蜂蜜蜂毒液（HBV）治疗比黄套毒液更频繁地诱导过敏反应[1]。基础血清胰蛋白酶水平升高的患者/乳细胞瘤患者面临更严重甚至致命反应的风险，并且可能无法接受毒液[2,3]。我们报告了患有惰性全身乳细胞诱变和反复性的患者的第一种情况严重的过敏反应到田间围栏和毒液，其中一剂omalizumab在两天内使其在两天内进行过冲，总剂量为351.11mg HBV（Alk Sq，Abello，Horsholm，DK）。此后，耐受10个维持剂量的HBV（100mg）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号